Zidovudine (ZDV), also known as azidothymidine (AZT), is an antiretroviral medication used to prevent and treat HIV/AIDS.<ref name=AHFS2016/> It is generally recommended for use with other antiretrovirals.<ref name=AHFS2016/> It may be used to prevent vertical transmission or after a needlestick injury or other potential exposure.<ref name=AHFS2016/> It is sold both by itself and together as lamivudine/zidovudine and abacavir/lamivudine/zidovudine.<ref name=AHFS2016/> It can be used by mouth or by slow intravenous.<ref name=AHFS2016></ref>
Common side effects include headaches, fever, and nausea.<ref name=AHFS2016/> Serious side effects include liver problems, myopathy, and lactic acidosis.<ref name=AHFS2016/> It is commonly used in pregnancy and appears to be safe for the baby.<ref name=AHFS2016/> ZDV is of the nucleoside analog reverse-transcriptase inhibitor (NRTI) class.<ref name=AHFS2016/> It works by inhibiting the enzyme reverse transcriptase that HIV uses to make DNA and therefore decreases replication of the virus.<ref name=AHFS2016/>
Zidovudine was first described in 1964.<ref></ref> It was approved in the United States in 1987 and was the first treatment for HIV.<ref name=AHFS2016/><ref></ref> It is on the WHO Model List of Essential Medicines, the safest and most effective medicines needed in a health system.<ref name="WHO21st"></ref> It is available as a generic medication.<ref name=AHFS2016/>